Many complex diseases manifest themselves differently in different people. Examples include kidney chronic kidney disease, heart failure and aneurysms. Similarly drug therapy that is effective in curing one disease often produces serious adverse events leading to other diseases. Target cancer drugs while effectively treating cancers can lead to cardiac insufficiency and heart failure in some patients, a phenomenon called cardiotoxicity.
Understanding the reasons for these variabilities is essential for the effective treatment of individuals. Precision Medicine is a new and integrative approach that takes into account biochemical, cell biological, genetic and environmental differences of individuals in order to predict the progression and treatment of disease. Precision Medicine requires a holistic systems‐based approach in order to understand how an individual’s genomic characteristics are translated into physiology under different social determinants. Built on pioneering research in basic systems biology, the Institute for Systems Biomedicine is establishing dialogue between multiple disciplines to develop tomorrow’s precision medicine.
Researchers in the Institute are part of the NIDDK funded Kidney Precision Medicine Consortium that is focused on building atlas at single cell resolution of the human kidney and a NHLBI funded program project grant with researchers at Yale and NYU to study the origins and progression of aortic aneurysms. Recently completed projects have developed numerous resources.
Institute researchers have developed a library of induced pluripotent stem cells from healthy individuals. These extensively characterized stem cells are available to all researchers from Mount Sinai and other academic institutions. Details of the stem cell library resource is provided here.
Institute researchers have conducted an extensive study of the transcriptomic profiles FDA approved protein kinase inhibitor drugs in human iPSC derived cardiomyocytes to understand the origins of cardiotoxicity. Also available are computed risk scores for these data from FDA-pharmcovigiliance database FAERS. These integrated data sets are readily available here for download and further analyses to identify individual responses to these drugs.
Ravi Iyengar, PhD
Dorothy H. and Lewis Rosenstiel Professor
Mount Sinai Institute of Systems Biomedicine